Page last updated: 2024-11-07

neurokinin a(4-10)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Neurokinin A(4-10) is a hexapeptide fragment of neurokinin A, a neuropeptide involved in various physiological processes, including pain perception, inflammation, and smooth muscle contraction. It exhibits agonist activity at the neurokinin-1 receptor (NK-1R), a G protein-coupled receptor primarily expressed in the central and peripheral nervous systems. This fragment, unlike the full-length neurokinin A, displays a higher selectivity for NK-1R compared to other tachykinin receptors (NK-2R and NK-3R). Research on Neurokinin A(4-10) focuses on its potential as a therapeutic agent for conditions associated with NK-1R activation, such as pain, anxiety, and substance abuse. Studies have shown that Neurokinin A(4-10) can effectively reduce pain perception in animal models, suggesting its potential for pain management. Additionally, its ability to modulate neuronal activity in brain regions associated with anxiety and reward suggests its potential for treating anxiety disorders and substance dependence.'

neurokinin A(4-10): bronchospastic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122230
CHEMBL ID126294
MeSH IDM0158207

Synonyms (12)

Synonym
CHEMBL126294 ,
nka-(4-10)
3-amino-n-(1-{1-[1-({[1-(1-carbamoyl-3-methylsulfanyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-carbamoyl)-2-methyl-propylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-hydroxy-ethyl)-succinamic acid
bdbm50001451
(3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]am
l-methioninamide, l-alpha-aspartyl-l-seryl-l-phenylalanyl-l-valylglycyl-l-leucyl-
neurokinin a(4-10)
HY-P0236
DTXSID50913838
23-amino-17-benzyl-7,10,13,16,19,22-hexahydroxy-5-[hydroxy(imino)methyl]-20-(hydroxymethyl)-8-(2-methylpropyl)-14-(propan-2-yl)-2-thia-6,9,12,15,18,21-hexaazapentacosa-6,9,12,15,18,21-hexaen-25-oic acid
(5s,8s,14s,17s,20s,23s)-23-amino-17-benzyl-5-carbamoyl-20-(hydroxymethyl)-8-isobutyl-14-isopropyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazapentacosan-25-oic acid
asp-ser-phe-val-gly-leu-met-nh2

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Tachykinin NK2 receptor antagonists could reduce motility and symptoms during gastrointestinal diseases characterized by local inflammation such as diarrhea or colitis; however, how these conditions change pharmacodynamic and pharmacokinetic characteristics of NK2 receptor antagonists is unknown."( Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models.
Bueno, L; Carini, F; Crea, A; Criscuoli, M; D'Aranno, V; Fioramonti, J; Giuliani, S; Lecci, A; Maggi, CA; Marinoni, E; Tramontana, M, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
" In the castor oil model, the oral/intraduodenal bioavailability of nepadutant was also determined."( Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models.
Bueno, L; Carini, F; Crea, A; Criscuoli, M; D'Aranno, V; Fioramonti, J; Giuliani, S; Lecci, A; Maggi, CA; Marinoni, E; Tramontana, M, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Thus, we have compared the actions of the selective neurokinin 1 (NK1) (CP-99,994) and neurokinin 2 (NK2) (SR-48,968) receptor antagonists against dose-response curves (DRC) induced by intravenously administered substance P (SP), neurokinin A (NKA), neurokinin B (NKB), beta Ala8-NKA (4-10),Sar9-Met(O2)11SP, and single dose (intravenous) challenge with resiniferatoxin (RTX), a capsaicin-like sensory neurotoxin, leukotriene D4 (LTD4) and antigen."( NK1 and NK2 receptors mediate tachykinin and resiniferatoxin-induced bronchospasm in guinea pigs.
Champion, E; Foulon, DM; Jones, TR; Masson, P; Rodger, IW, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-K receptorMesocricetus auratus (golden hamster)IC50 (µMol)0.00600.00100.03530.1480AID211530
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID211530Competitive inhibition of [125I]NKA binding to hamster urinary bladder Tachykinin receptor 21992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
A new class of high affinity ligands for the neurokinin A NK2 receptor: psi (CH2NR) reduced peptide bond analogues of neurokinin A4-10.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (12.90)18.7374
1990's22 (70.97)18.2507
2000's5 (16.13)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.37 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]